

# Protocol after the ILSI/HESI International Act. Study



(as of 2003)



## ■ Preliminary test

Period: 4 weeks

Animals: wild type (non-Tg for rasH2)

Purpose: Dose finding for 26-week study

## ■ Carcinogenicity test

Period: 26 weeks

Group composition:

GM: nega. con. group + 3 dose groups + posi. con. group

wild type (non-Tg): nega. con. group + high-dose group.

(crucial)

Animal: 25/sex/group

**Robinson D.E. & MacDonald J. S.,  
Toxicol. Pathol. 29 (Suppl.): 13-19 (2001)**

# Present protocol for the FDA application

(interview from people in US CROs & Pharmaceuticals)



## ■ Preliminary test

Period: 4 weeks

Animals: wild type (non-Tg for rasH2)

10 mice /sex/group + TK

## ■ Carcinogenicity test

Period: 26 weeks

Group composition:

GM: nega. con. group + 3 dose groups + posi. con. group

wild type (non-Tg): no need (stated by FDA in DIA, 2005)

Animal: 25 mice/sex/group + TK

15 mice/sex for positive control group (from Nov. 2009)